Preventive Effect of PEGylated Recombinant Human Granulocyte Stimulating Factor on Bone Marrow Suppression after Chemoradiotherapy for Cervical Cancer
This article explores the clinical value of preventing the use of PEGylated recombinant human granulocyte stimulating factor in the prevention of myelosuppression during concurrent chemoradiotherapy of cervical cancer. The study group received PEG⁃rhG⁃CSF 6mg subcutaneous injection + recombinant human granulocyte colony-stimulating factor (rhG - CSF) 150ug subcutaneous injection when ANC decreased for the first time in concurrent chemoradiotherapy. Analysis of ANC and ANC reduction at each time in each group of patients led to delayed incidence of chemoradiotherapy and time to adverse reaction. The results showed that the ANC of the study group was significantly higher than that of the control group at each time after administration, and the difference was statistically significant (P<0.05). The ANC of the study group patients returned to normal after 48 hours of administration. The incidence of delayed chemoradiotherapy in the two groups after treatment was 24% and 65%, respectively, and the difference was statistically significant (P<0.05). There was no significant difference in adverse drug reactions between the two groups after administration. The time to remission of fever and bone pain after administration was significantly shorter in the study group than in the control group (P<0.05). Prevention of PEG⁃rhG⁃CSF can reduce the incidence of ANC reduction, and it has important clinical value in reducing the treatment discontinuation caused by myelosuppression and improving the efficacy of radiotherapy and chemotherapy in patients with cervical cancer.